TOP > 外国特許検索 > NARROW-SPECTRUM ANTIBACTERIAL ANTIBIOTICS TARGETING SPECIFIC TYPES OF BACTERIA THAT SYNTHESIZES MENAQUINONE THROUGH AN ALTERNATIVE PATHWAY VIA FUTALOSINE OR 6-AMINODEOXYFUTALOSINE AS AN INTERMEDIATE.

NARROW-SPECTRUM ANTIBACTERIAL ANTIBIOTICS TARGETING SPECIFIC TYPES OF BACTERIA THAT SYNTHESIZES MENAQUINONE THROUGH AN ALTERNATIVE PATHWAY VIA FUTALOSINE OR 6-AMINODEOXYFUTALOSINE AS AN INTERMEDIATE.

外国特許コード F160008799
整理番号 (S2014-1273-N0)
掲載日 2016年8月4日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP004928
国際公開番号 WO 2016051767
国際出願日 平成27年9月29日(2015.9.29)
国際公開日 平成28年4月7日(2016.4.7)
優先権データ
  • 62/057,632P (2014.9.30) US
発明の名称 (英語) NARROW-SPECTRUM ANTIBACTERIAL ANTIBIOTICS TARGETING SPECIFIC TYPES OF BACTERIA THAT SYNTHESIZES MENAQUINONE THROUGH AN ALTERNATIVE PATHWAY VIA FUTALOSINE OR 6-AMINODEOXYFUTALOSINE AS AN INTERMEDIATE.
発明の概要(英語) Alternative menaquinone biosynthetic pathway via futalosine or 6-aminodeoxyfutalosine as an intermediate (futalosine pathway) is an attractive target for new narrow-spectrum antimicrobial agents. Siamycin I and fatty acids were provided as selective antimicrobial activity against bacteria such as Helicobacter and Campylobacter, which depend on the futalosine pathway to grow. Specifically, siamycin I and omega-3 polyunsaturated fatty acids inhibited the colonization of H. pylori in vivo and thus siamycin I and omega-3 polyunsaturated fatty acids could be a new narrow-spectrum antibiotic for Helicobacter and Campylobacter
特許請求の範囲(英語) [claim1]
1. Siamycin I or a fatty acid for the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and
wherein the siamycin I or a fatty acid inhibits the futalosine pathway in the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject.
[claim2]
2. Siamycin I or a fatty acid for inhibiting synthesis of menaquinone through the futalosine pathway by a bacterium in a subject who is infected by the bacterium comprising administration of siamycin I or a fatty acid to the subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and
wherein the siamycin I or a fatty acid inhibits the futalosine pathway.
[claim3]
3. The Siamycin I or a fatty acid of claim 1 or 2, wherein the bacterium is selected from a group consisting of genus of Helicobacter, Campylobacter, Wolinella and Streptomyces.
[claim4]
4. The Siamycin I or a fatty acid of claim 1 or 2, wherein the bacterium is a Helicobacter pylori,
[claim5]
5. The Siamycin I or a fatty acid of claim 1 or 2, wherein the fatty acid is at least one fatty acid that is selected from a group consisting of omega-3 fatty acids, α-linolenic acid, EPA, DHA, oleic acid, linoleic acid, and arachidonic acid.
[claim6]
6. A method for the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject comprising administration of siamycin I or a fatty acid to the subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and
wherein the siamycin I or a fatty acid inhibits the futalosine pathway.
[claim7]
7. A method for inhibiting synthesis of menaquinone through the futalosine pathway by a bacterium in a subject who is infected by the bacterium, comprising administration of siamycin I or a fatty acid to the subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and
wherein the siamycin I or a fatty acid inhibits the futalosine pathway.
[claim8]
8. A pharmaceutical composition comprising siamycin I or a fatty acid for use in treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and wherein the siamycin I or a fatty acid inhibits the futalosine pathway in the treatment or prevention of bacterial infections or the diseases caused by bacterial infections in a subject.
[claim9]
9. A pharmaceutical composition comprising siamycin I or a fatty acid for use in inhibiting synthesis of menaquinone through the futalosine pathway by bacterium in a subject who is infected by the bacterium comprising administration of siamycin I or a fatty acid to the subject,
wherein the bacterium synthesize menaquinone through the futalosine pathway, and
wherein the siamycin I or a fatty acid can inhibit the futalosine pathway.
[claim10]
10. A method for the prevention of bacterium propagation in food, feedstuff or drinking water that contain siamycin I or a fatty acid.
[claim11]
11. The method of claim 10, wherein feedstuff or drinking water application in combating Campylobacter propagation in poultry.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • THE KITASATO INSTITUTE
  • 発明者(英語)
  • OMURA SATOSHI
  • MATSUI HIDENORI
  • NAKANO HIROFUMI
  • YAMAMOTO TSUYOSHI
  • YAMAJI KENZABURO
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close